Tuberculosis Vaccine Developments and Efficient Delivery Systems: A Comprehensive Appraisal

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Feb 26

PMID 38404880

Authors

Rasoul Hoseinpour

Alka Hasani

Behzad Baradaran

Jalal Abdolalizadeh

Roya Salehi

Akbar Hasani

Edris Nabizadeh

Mina Yekani

Roqaiyeh Hasani

Hossein Samadi Kafil

Khalil Azizian

Mohammad Yousef Memar

Affiliations

Soon will be listed here.

Abstract

Despite the widespread use of the Bacillus Calmette-Guérin (BCG) vaccine, (MTB) continues to be a global burden. Vaccination has been proposed to prevent and treat tuberculosis (TB) infection, and several of them are in different phases of clinical trials. Though vaccine production is in progress but requires more attention. There are several TB vaccines in the trial phase, most of which are based on a combination of proteins/adjuvants or recombinant viral vectors used for selected MTB antigens. In this review, we attempted to discuss different types of TB vaccines based on the vaccine composition, the immune responses generated, and their clinical trial phases. Furthermore, we have briefly overviewed the effective delivery systems used for the TB vaccine and their effectiveness in different vaccines.

Citing Articles

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.

PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.

References

Montalvo-Quiros S, Vallet-Regi M, Palacios A, Anguita J, Prados-Rosales R, Gonzalez B . Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis. Pharmaceutics. 2020; 12(12). PMC: 7767215. DOI: 10.3390/pharmaceutics12121218. View

Huang C, Hsieh W . Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Hum Vaccin Immunother. 2017; 13(9):1960-1971. PMC: 5612516. DOI: 10.1080/21645515.2017.1335374. View

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

Andersen C, Dietrich J, Agger E, Lycke N, Lovgren K, Andersen P . The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun. 2006; 75(1):408-16. PMC: 1828435. DOI: 10.1128/IAI.01290-06. View

Hesseling A, Cotton M, von Reyn C, Graham S, Gie R, Hussey G . Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008; 12(12):1376-9. View

Ndiaye B, Thienemann F, Ota M, Landry B, Camara M, Dieye S . Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015; 3(3):190-200. PMC: 4648060. DOI: 10.1016/S2213-2600(15)00037-5. View

Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

Liu H, Tu Z, Feng F, Shi H, Chen K, Xu X . Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Acta Pharm. 2015; 65(2):105-16. DOI: 10.1515/acph-2015-0019. View

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

10.

Duthie M, Coler R, Laurance J, Sampaio L, Oliveira R, Sousa A . Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis. Infect Immun. 2014; 82(9):3979-85. PMC: 4187809. DOI: 10.1128/IAI.02145-14. View

11.

Zhou F, Zhang D . Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice. Viruses. 2023; 15(10). PMC: 10612075. DOI: 10.3390/v15102123. View

12.

Gheibi Hayat S, Darroudi M . Nanovaccine: A novel approach in immunization. J Cell Physiol. 2019; 234(8):12530-12536. DOI: 10.1002/jcp.28120. View

13.

Das I, Padhi A, Mukherjee S, Dash D, Kar S, Sonawane A . Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of γδ T cells in mice. Nanotechnology. 2017; 28(16):165101. DOI: 10.1088/1361-6528/aa60fd. View

14.

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S . Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine. 2017; 35(12):1652-1661. DOI: 10.1016/j.vaccine.2017.01.055. View

15.

Nyendak M, Swarbrick G, Duncan A, Cansler M, Huff E, Hokey D . Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine. Sci Rep. 2016; 6:36355. PMC: 5141283. DOI: 10.1038/srep36355. View

16.

Azzopardi P, Bennett C, Graham S, Duke T . Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis. 2009; 13(11):1331-44. View

17.

Kumarasamy N, Poongulali S, Beulah F, Akite E, Ayuk L, Bollaerts A . Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial. Medicine (Baltimore). 2018; 97(45):e13120. PMC: 6250513. DOI: 10.1097/MD.0000000000013120. View

18.

Kaufmann S . Future vaccination strategies against tuberculosis: thinking outside the box. Immunity. 2010; 33(4):567-77. DOI: 10.1016/j.immuni.2010.09.015. View

19.

Ottenhoff T . A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med. 2020; 382(16):1576-1577. DOI: 10.1056/NEJMc2001364. View

20.

Mendez-Samperio P . Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis. Scand J Immunol. 2016; 84(4):204-10. DOI: 10.1111/sji.12465. View